(Nasdaq: INBS) Is at the Top of Our Watchlist This Morning — A Tiny Float, Six Completed Clinical Studies, and Margins Approaching 49%

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Krypton Street Just Put (Nasdaq: INBS) On This Morning’s Watchlist—Tuesday, September 1, 2026 Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up (INBS) While It’s Still Early… September 1, 2026 Dear Reader, As the countdown to Tuesday’s session begins, (Nasdaq: INBS) is moving back onto the screen with several important pieces lining up at once. Krypton Street continues to watch for companies where emerging technology, large end markets, and a tight share structure come together in a way that can quickly draw attention. Intelligent Bio Solutions Inc. (Nasdaq: INBS) checks every one of those boxes right now. This is a medtech company with a proprietary fingerprint-based dr-ug screening system that collects sweat samples in seconds and delivers results in under ten minutes. No urine cups, no oral swabs, no lab queues, no specialist technicians. The system works at the point of collection — on a job site, at a warehouse gate, at a mine entrance — and the company just reported 38% full-year revenue growth with gross margins approaching 49%. But the real reason our team is bringing this name to the community today is what's happening on the regulatory side… All clinical data collection across the company's FDA 510(k) study program is now complete, and the submission is on track for the second half of calendar 2026. If clearance comes through, it could open the door to the largest dr-ug screening market in the world — and with a float this tight, our community needs to understand the mechanics before that potential catalyst arrives. Intelligent Bio Solutions Inc. (Nasdaq: INBS) is topping our watchlist this morning—Tuesday, September 1, 2026. According to Yahoo Finance, (Nasdaq: INBS) has a float less than 3M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. In August alone, INBS made an approx. 102% move from around $1.72 on 8/04/2026 to $3.49 on 8/17/2026, according to Barchart. How This Technology Actually Works Let's break down what our community is looking at here. The Intelligent Fingerprinting Dr-ug Screening System uses fingerprint sweat analysis — a proprietary, non-invasive approach — to screen for recent use of op-ia-tes, co-ca-ine, me-tham-pheta-mine, and can-na-bis. A donor presses a fingertip onto a cartridge, the reader device processes the sample, and results come back at the point of collection. Sample collection takes seconds. Results in under ten minutes. No bodily fluids collected in the traditional sense. Think about what that means for a construction foreman or a logistics manager who needs to screen a crew before the shift starts… No clinic visit. No waiting room. No chain-of-custody paperwork bouncing between a job site and an off-site lab. The entire workflow stays on-site, stays fast, and stays simple. We've seen how innovation in other testing categories — glucose monitoring, rapid antigen testing — reshaped entire markets once the technology became portable and accessible. The same dynamics could apply here, and the company is building the commercial infrastructure to capture that shift. The company's usability study, completed in August 2026, confirmed that operators with no specialist background could be trained to administer the system effectively. Fifteen operators participated, and the outcome showed this is a tool built for workplace safety personnel, not laboratory professionals. Peter Passaris, Vice President of Product Development, noted that the simpler and more reliable the screening process, the stronger the company's position in the market. That matters because the sectors driving demand — construction, manufacturing, transport and logistics, mining — are exactly the environments where sending workers off-site for dr-ug testing creates cost, delay, and operational friction… Intelligent Bio Solutions Inc. (Nasdaq: INBS) already serves 502 active customers across the UK, Europe, APAC, and the Middle East. Its reader installed base has grown 22% year-over-year to 1,886 units, and each reader placed in the field generates recurring demand for consumable cartridges — a razor-razorblade revenue model where cartridge consumption grew 35% year-over-year to 106,500 units, outpacing the installed base growth rate. That pattern — faster cartridge growth than hardware growth — tells our community that existing customers are using the system more, not less. That's recurring revenue accelerating, and it's the metric that matters most when evaluating whether a razor-razorblade model is scaling the way it should. The company also recently secured its eighth European patent grant, further protecting its proprietary fingerprint screening technology. The FDA Program Our Community Should Understand Here's where the potential catalyst comes into focus… The company has now completed a structured, multi-study clinical and technical program supporting its FDA 510(k) submission — the regulatory gateway to the U.S. dr-ug screening market, the largest on earth. Our community should understand the scope of what was accomplished, because each study adds a layer of evidence to the submission package. Precision testing confirmed reproducibility across more than 1,600 tests, three production runs, and three independent sites — demonstrating that results stay consistent regardless of where or how the system is manufactured and operated. An interference study evaluated whether everyday contaminants — hand creams, oils, dirt, water — affect accuracy under real-world field conditions. This is the kind of field-readiness data that separates a concept from a deployable tool. A method comparison study enrolled 135 participants across three independent U.S. clinical sites, measuring sensitivity, specificity, and accuracy in occupational screening environments, with independent verification via LC-MS/MS analysis. Independent penetration testing found no major cybersecurity vulnerabilities, and all review items have been resolved — 100% of medium-risk items remediated, all 19 software bill of materials vulnerabilities cleared. And ISO 13485:2016 recertification aligns the company's quality management framework with the FDA's newly amended Quality Management System Regulation. The submission targets codeine detection as the initial indication. Clearance could open the door to U.S. market entry beyond current Forensic Use Only settings — spanning workplace testing, criminal justice, pain management, and substance abuse treatment… The global dr-ug screening sector is valued at roughly $8.29B in 2026 and projected to reach $25.3B by 2036, according to ResearchAndMarkets. North America leads the sector, and that is where (INBS) is headed next. The significance of that potential market entry is worth our community pausing on. Right now, the Intelligent Fingerprinting system is commercially deployed outside the U.S. across workplace, law enforcement, and government settings. FDA clearance would give the company access to a market where federal mandates, corporate compliance programs, and a growing substance-abuse concern are all converging. The Revenue and Margin Story The fiscal 2026 full-year results show a company that's already generating real commercial traction — not just preparing for a future event. Total revenue reached $4.2M, a 38% increase year-over-year. Gross margin expanded to 48.63%, up 778 basis points… That margin expansion came from the transition to Syrma Johari as a manufacturing partner — expected to deliver annual production cost savings of more than 40% and an expected gross margin improvement of approximately 20 percentage points — combined with an optimized product mix weighted toward higher-margin consumable cartridges. A strategic partnership with Bouygues UK, part of global construction group Bouygues Construction, adds a significant new customer in a high-profile, safety-critical construction environment — the kind of deployment that demonstrates the system's readiness at enterprise scale. And there's one more detail worth flagging for our community… The company is validating a rapid screening cartridge targeting 70% faster results — which could further differentiate the system in field environments where speed matters most. Harry Simeonidis, President and CEO, noted: "We are now firmly in the final stretch of data analysis and assembly of our FDA 510(k) submission package, and we remain focused on bringing our technology to the U.S. market." 8 Factors Putting (INBS) On Our Watchlist This Morning—Tuesday, September 1, 2026… 1. Tight Float: According to Yahoo Finance, INBS has fewer than 3M shares listed as available to the public, a structure that can produce sharp moves when demand shifts. 2. Recent Movement: During August, INBS moved approximately 102% from around $1.72 on August 4 to $3.49 on August 17, demonstrating how quickly the name has moved previously. 3. FDA Progress: With clinical data collection across its FDA 510(k) study program complete, INBS says its submission remains on track for the second half of calendar 2026. 4. Revenue Growth: Fiscal 2026 revenue reached $4.2M, representing 38% year-over-year growth for INBS as commercial activity continued expanding. 5. Margin Expansion: Gross margin climbed to 48.63%, up 778 basis points, giving INBS another fundamental metric worth examining alongside its revenue growth. 6. Customer Footprint: With 502 active customers across the UK, Europe, APAC, and the Middle East, INBS already has an established commercial presence outside the U.S. 7. Recurring Demand: The installed reader base for INBS grew 22% year over year to 1,886 units while cartridge consumption increased 35% to 106,500 units. 8. Patent Expansion: After recently securing its eighth European patent grant, INBS continues building intellectual-property protection around its proprietary fingerprint screening technology. Pull Up (INBS) While It’s Still Early… Our community is watching a name where a proprietary, field-ready screening technology is generating compounding commercial traction internationally… while simultaneously approaching the single largest potential catalyst in the company's history — FDA clearance for the U.S. market. The company's Intelligent Fingerprinting system is already deployed outside the U.S. across workplace, law enforcement, and government settings. What the FDA pathway represents is the chance to bring a proven, commercially validated screening platform into the single largest addressable market in its sector — backed by manufacturing cost savings that could dramatically expand margins and a razor-razorblade model that's already demonstrating accelerating recurring revenue. With a float under 3M shares, the structure of Intelligent Bio Solutions Inc. (Nasdaq: INBS) is at the very top of our watchlist this morning, Tuesday, September 1, 2026. Pull up (INBS) while it’s still early. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 08/31/2026 and ending on 09/01/2026 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid twenty three thousand five hundred USD (“Funds”). These Funds were part of the thirty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/inbs-nuPmQ/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe About our service provider Sent by alex@kryptonstreet.com

Pull Up (Nasdaq: INBS) Right Now — A Completed FDA Evidence Package, 778 Basis Points of Margin Expansion, and a Float Under 3M Shares

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Intelligent Bio Solutions Inc. (Nasdaq: INBS) Just Landed On Our Watchlist This Morning—Tuesday, September 1, 2026… Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At (INBS) While It’s Still Early… September 1, 2026 Dear Reader, With less than 90 minutes until the opening bell, (Nasdaq: INBS) is back on the radar after a string of developments that make its fingerprint-based screening platform difficult to ignore. The biggest names in dr-ug screening have been doing things the same way for decades. Urine cups. Oral swabs. Lab queues. Chain-of-custody paperwork that can stretch resolution timelines from hours into days. These methods work. But they're slow, they're invasive, and in a world that increasingly demands speed and portability in every other category of field testing, the standard approach to workplace dr-ug screening has barely moved since the 1990s. Think about that for a moment. We've reinvented how we screen for disease, how we monitor blood sugar, how we test for pathogens — but the way a construction foreman confirms that a crane operator is fit for duty still involves a trip to a clinic and a plastic cup. Which is exactly why Intelligent Bio Solutions Inc. (Nasdaq: INBS) deserves a closer look right now. This medtech company has built something fundamentally different… a portable screening system that collects samples from fingerprint sweat in seconds and delivers results in under ten minutes. No needles. No cups. No lab wait times. No specialized technicians required. And the timing could not be more compelling. The global dr-ug screening sector is valued at roughly $8.29B in 2026 and projected to reach approximately $25.3B by 2036, according to ResearchAndMarkets — reflecting an 11.8% compound annual growth rate. North America leads the sector, driven by tightening compliance mandates, expanded workplace safety regulations, and growing adoption of rapid on-site testing. That's the backdrop. Now here's what makes (INBS) stand out in that context. Intelligent Bio Solutions Inc. (Nasdaq: INBS) is topping our watchlist this morning—Tuesday, September 1, 2026. (Nasdaq: INBS) has a float less than 3M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. In August alone, INBS made an approx. 102% move from around $1.72 on 8/04/2026 to $3.49 on 8/17/2026, according to Barchart. What a Fingerprint Can Reveal The core technology is the Intelligent Fingerprinting Dr-ug Screening System. It uses fingerprint sweat analysis — a proprietary, non-invasive method — to screen for recent use of opiates, cocaine, methamphetamine, and cannabis. The system collects sweat samples directly from a donor's fingertip, analyzes them through a reader device, and returns results at the point of collection. Sample collection takes seconds. Results arrive in under ten minutes. The entire workflow is designed for the field — job sites, transport depots, distribution centers, mining operations — places where traditional lab-based testing creates logistical headaches and operational delays. And the company's usability study, completed in August 2026, confirmed that operators with no specialist background could be trained to administer the system effectively. Fifteen operators participated, and the outcome reinforced that this is a tool built for workplace safety personnel — not laboratory technicians. Peter Passaris, Vice President of Product Development, noted that the simpler and more reliable the screening process, the stronger the company's position in the market. That's the kind of advantage that compounds over time… Intelligent Bio Solutions Inc. (Nasdaq: INBS) already serves 502 active customers across the UK, Europe, APAC, and the Middle East. Its reader installed base has grown 22% year-over-year to 1,886 units, with each reader placement creating recurring demand for consumable cartridges — the foundation of the company's razor-razorblade revenue model. The company also recently strengthened its European IP portfolio with its eighth patent grant, further protecting its proprietary fingerprint-based screening technology. Closing in on the FDA Here is where the story gets particularly worth watching… Intelligent Bio Solutions Inc. (INBS) is in the final stages of assembling its FDA 510(k) submission package — the regulatory gateway to the U.S. dr-ug screening market, the largest on earth. Throughout fiscal 2026 and into early fiscal 2027, the company executed a structured, multi-study clinical program designed to address every dimension the FDA evaluates: safety, accuracy, usability, specificity, security, and precision. The depth of that program is worth understanding, because each study adds a layer of evidence to the submission package. Precision testing confirmed reproducibility across more than 1,600 tests, three production runs, and three independent sites — demonstrating that the system delivers consistent results regardless of where or how it's manufactured and operated. An interference study evaluated whether everyday contaminants — hand creams, oils, dirt, water — affect the system's accuracy under real-world conditions. This is the kind of field-readiness testing that separates a lab concept from a deployable tool. A method comparison study enrolled 135 participants across three independent U.S. clinical sites over three weeks, measuring sensitivity, specificity, and accuracy in occupational screening environments. All specimens are being independently verified via LC-MS/MS analysis. Independent third-party penetration testing identified no major cybersecurity vulnerabilities — and all review items have since been resolved, with 100% of medium-risk items remediated and all 19 software bill of materials vulnerabilities fully cleared. And the company recently recertified under ISO 13485:2016, the internationally recognized quality management standard for medical device manufacturers — which now aligns with the FDA's newly amended Quality Management System Regulation. All clinical data collection across the company's FDA 510(k) clinical study program is now complete. The 510(k) submission is on track for the second half of calendar 2026… That submission targets codeine detection as the initial indication — and clearance could open the door to U.S. market entry beyond current Forensic Use Only settings, spanning workplace testing, criminal justice, pain management, law enforcement, and substance abuse treatment. The significance of that clearance is hard to overstate. Right now, the Intelligent Fingerprinting system is commercially deployed outside the U.S. across workplace, law enforcement, and government settings. FDA clearance would give the company access to the single largest dr-ug screening market in the world — one where federal mandates, corporate compliance programs, and a growing substance abuse concern are all pushing demand in the same direction. Already Building Revenue While the FDA pathway is the headline, the numbers underneath tell a compelling story on their own. Intelligent Bio Solutions Inc. (INBS) just reported its fiscal 2026 full-year results — and the trajectory is clear. Total revenue reached $4.2M, a 38% increase year-over-year. Gross margin expanded to 48.63%… up 778 basis points from the prior year. That margin expansion reflected a strategic combination: the transition to Syrma Johari as a high-quality, lower-cost manufacturing partner — expected to deliver annual production cost savings of more than 40% and an expected gross margin improvement of approximately 20 percentage points — along with an optimized product mix weighted toward higher-margin consumable cartridges. Consumable cartridge output reached 106,500 units, a 35% increase that outpaced the rate of installed base growth and confirmed deepening utilization among existing customers. That dynamic is worth pausing on… When cartridge consumption grows faster than the reader base, it signals that customers who already have the hardware are using it more. That's recurring revenue accelerating — exactly the pattern a razor-razorblade model is built to generate. The company also secured a partnership with Bouygues UK, part of global construction group Bouygues Construction, for a dr-ug-testing rollout across a high-profile, safety-critical construction environment — exactly the kind of customer that validates the system's field readiness at scale. And there's another detail worth noting… The company is validating a rapid screening cartridge targeting 70% faster results — which could further differentiate the system in field environments where speed matters most. Harry Simeonidis, President and CEO, said it well: "We are now firmly in the final stretch of data analysis and assembly of our FDA 510(k) submission package, and we remain focused on bringing our technology to the U.S. market." 7 Reasons Why We're Watching (INBS) This Morning… 1. Small-Float: According to Yahoo Finance, less than 3M shares exist in the public float, the potential exists for big moves if demand begins to shift. 2. 38% Revenue Growth: Fiscal 2026 full-year revenue reached $4.2M, a 38% year-over-year increase driven by a 22% expansion in the reader installed base and a 35% jump in consumable cartridges, per the company's latest results. 3. FDA 510(k) Approaching: All clinical data collection across the company's FDA 510(k) study program is complete, with submission targeting H2 2026 for codeine detection clearance and planned U.S. market entry. 4. Reproducibility Confirmed Across 1,600+ Tests: Precision testing confirmed consistent, reliable results across more than 1,600 tests, three production runs, and three independent sites — adding depth to the submission package. 5. Expanding Gross Margin: Gross margin expanded to 48.63%, up 778 basis points year-over-year, reflecting the transition to Syrma Johari as a manufacturing partner expected to deliver 40%+ production cost savings and approximately 20 percentage points of annual gross margin improvement. 6. ISO 13485:2016 Recertification: The company recertified to the internationally recognized quality management standard for medical device manufacturers, aligning with the FDA's newly amended Quality Management System Regulation. 7. Bouygues UK Partnership: A strategic partnership with Bouygues UK, part of global construction group Bouygues Construction, adds a significant new customer in a high-profile, safety-critical environment. Take A Look At (INBS) While It’s Still Early… There's a version of this story where a company builds a novel, non-invasive screening technology… proves it works across more than half a dozen clinical and technical studies… scales it commercially to 502 active customers and $4.2M in annual revenue with expanding margins… and then unlocks the largest dr-ug screening market on earth with a single regulatory clearance. That version may already be underway with Intelligent Bio Solutions Inc. (Nasdaq: INBS). Which is why (INBS) is at the top of our watchlist this morning, Tuesday, September 1, 2026. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 08/31/2026 and ending on 09/01/2026 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, JRZ Capital LLC has paid TD Media LLC thirty five thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid three hundred fifty nine thousand five hundred USD (“Funds”). These Funds were part of the thirty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/inbs-nuPmQ/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe About our service provider Sent by jeff@stocknewstrends.com

Today's Radar Puts (NYSE American: GORO) In The Spotlight (6 Key Potential Catalysts)

Did you catch this?

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on behalf of Goldgroup Mining Inc. Today's Radar Puts (NYSE American: GORO) In The Spotlight (6 Key Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* September 1st Greetings, Friend! Did you catch this? On August 17th, 2026, Goldgroup Mining Inc. (NYSE American: GORO) released selected drill results from the Don David gold and silver mine in Oaxaca. The headline figures were not the intercepts but the volume behind them: 25,726 metres across 123 holes in the seven months to July 31st, drilled with as many as five underground rigs and two surface rigs working at once. The grades did their part. Hole 525086 on the Sadie 1 vein returned 1.92 metres of estimated true width at 13.49 grams per tonne gold and 931 grams per tonne silver. Hole 426017 at Alta Gracia, a greenfield target outside the producing complex, cut 3.26 metres at 3.34 grams per tonne gold and 1,079 grams per tonne silver. Chairman and interim Chief Executive Officer Javier Reyes said the aim is to "continue discovering and defining mineralization with potential to extend mine life, grow our resource base and create long-term shareholder value." That drilling belongs to a company that looked very different two months earlier. Goldgroup and Gold Resource Corporation closed a business combination on July 17th, 2026. Gold Resource delisted from the NYSE American and Goldgroup took the GORO symbol, adding Don David and the Michigan Back Forty project to the two Sonoran assets it already held. The combined company reports four 100% owned properties, two of them producing, cash of US$46Mn and no debt as of June 2026. Management describes a vision of more than 250,000 ounces of gold equivalent annual output. The Sector Backdrop The metal has done a great deal of the work. Gold was quoted near $4.67K per ounce in late August 2026, roughly 40% above where it stood twelve months earlier. J.P. Morgan Global Research currently forecasts gold reaching $6K per ounce by the end of 2026 and $6.3K by the end of 2027, citing central bank demand, reserve diversification away from dollar assets and hedging against fiscal and geopolitical risk. Prices at that level change the arithmetic for small producers in two ways: existing ounces are worth more, and previously marginal deposits move back onto the drawing board. Goldgroup's own Back Forty assessment illustrates the point, modeling an after tax net present value of $214Mn at $1.8K per ounce gold and $556Mn at a consensus price of $3.04K. About The Company: Goldgroup Mining Inc. (NYSE American: GORO) The business sells gold and silver with copper, lead and zinc credits. Don David is an underground mine on 55,000 hectares in Oaxaca feeding a 1,800 tonne per day flotation plant, with 37,000 to 52,000 ounces of gold equivalent expected in 2026 and measured and indicated resources of 1.49Mn tonnes at 3.88 grams per tonne gold equivalent. Cerro Prieto is an open pit heap leach in Sonora producing since 2013, with an in house 2026 estimate of 17,000 to 20,000 plus ounces. San Francisco, acquired outright in June 2026, holds 1.23Mn measured and indicated ounces and 16,875 tonnes per day of installed crushing, with a restart targeted for 2027. Back Forty in Michigan's Upper Peninsula carries 14.5Mn tonnes at 2.21 grams per tonne gold, 27 grams per tonne silver, 0.38% copper and 3.35% zinc, and entered a definitive feasibility study under SLR Engineering. Behind The Scenes Two governance items sit behind the operating news.  On July 20th, Eric Sprott reported holding 10,084,746 common shares and 3,963,063 warrants following the arrangement, roughly 7.5% of the company non diluted and 10.1% partially diluted, stating the shares are held with a long term view. One week later the board announced a leadership transition: Allen Palmiere left the Chief Executive Officer role, chairman Javier Reyes stepped in on an interim basis, and a search for a permanent appointment began while integration continued. Tracking 6 Key Potential Catalysts Backing (NYSE American: GORO) #1. A Full Sweep Of Bullish Readings On Barchart Right Now. All 13 technical indicators tracked by Barchart are flashing bullish on GORO, across short, medium and long terms including the website’s composite “Trend Seeker” indicator. #2. Four Wholly Owned Assets Spread Across Two Jurisdictions. Mexico supplies the production and the restart candidate while Michigan supplies North American development exposure, giving GORO more than one path forward. #3. A Feasibility Study Underway On A Polymetallic Michigan Deposit. Back Forty pairs gold with silver, copper and zinc credits and carries a precious metals stream with Osisko Gold Royalties, which shapes how GORO could fund its development. #4. Exploration Reaching Well Past The Producing Vein Systems. Marena North, Splay 31, Isabel SE and the San Juan vein set are all named as follow up targets, meaning GORO has a queue of drill ready ground. #5. A Metal Price Backdrop Analysts Expect To Hold Or Climb. With J.P. Morgan Global Research forecasting $6K per ounce gold by the end of 2026, revenue per ounce at GORO is set against a supportive price outlook. #6. Reported Cash Of $46Mn Against No Outstanding Debt. A clean balance sheet gives GORO room to fund drilling and studies before any restart decision, a position the company details for shareholders. In Summary Companies rarely change shape this quickly. In roughly eight weeks Goldgroup completed a merger, took a new listing, absorbed two additional assets, changed its Chief Executive Officer and put drills on three properties at once. The market now has a set of concrete milestones to watch rather than promises: the San Francisco technical study, the balance of the 26,053 metre program, the Back Forty feasibility work and a permanent leadership appointment. Mineral resources are not mineral reserves and none of the development scenarios are decisions yet. Even so, a producer with cash, no debt and four owned properties in a record gold market is a name that earns a place on our watchlist. We’re kicking-off coverage on Goldgroup Mining Inc. (NYSE American: GORO). Updates will be coming soon. Stay tuned. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 08/31/2026 and ending on 09/01/2026 to publicly disseminate information about (GORO:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named Sideways Frequency LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (GORO:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/goro-mlrqh/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice